Category Archives: Transhuman News

Today the general public is more ecologically conscious than it has ever been. The market for goods produced and sold under the sustainability banner is growing, and the push to become "green" permeates virtually all economic sectors. Areas such as manufacturers of automobiles, cleaning solutions, apparel and even fossil fuel products are bringing their billions to bear upon pollution, or so the marketing teams and advertisements claim. But out of all economic sectors, agriculture is the most intimately connected with human welfare.

Consumers rightfully desire to know what they are eating. The thought that even fresh, healthy foods could be laced with agrochemicals or biologically contaminated at the genetic level has driven an increasing preference for foods billed as organic or natural. Lumped into this category of ostensibly healthier foods are those billed as being free of GMOsgenetically modified organisms. Genetic modifications to crop plants are implied to be innately unnatural and therefore, somehow, detrimental to both human and biosphere health.

There are legitimate grievances to be made about modern industrial agriculture, but the use of modern biotechnology for the development of new crop varieties is not one of them. The marketing push for non-GMO foods is just that, a marketing push. The push is fortified through advertisements rooted in pseudoscience, anti-intellectualism and the romanticization of premodern agriculture. Consumers are right to be wary about potentially harmful food, but ecological problems must be solved by judiciously using science, rather than dispensing with it.

Genetic engineering is a maligned piece of terminology, avoided at all costs by manufacturers and vehemently shunned by some. In the context of modern agriculture, genetic engineering refers to the use of recombinant DNA technology to produce new crop varieties. Before this technology's introduction, plant breeders used the traditional methods of careful parent selection and crossbreeding to develop new crop varieties to improve crop yield, stress tolerance and disease resistance.

Ancient farmers selected plants with preferred traits when saving seed for the next planting. After many generations, this artificial selection domesticated relatively unappetizing crops into high-yielding, nutritious staples. Today, these procedures are augmented with a modern understanding of genetics.

Traditional breeding is a mixing of genetic material from within the same genome between closely related species of the same genus. Recombinant engineering, however, can transfer genes from distantly related plant lineages, and even material from bacteria, into other crop plants. As Ania Wieczorek and Mark Wright note in 'Nature," recombinant DNA technology was applied commercially beginning in the 70s, with the first engineered plant entering the market in 1982. Exogenous DNA, which is DNA found outside the original organism, can be transferred into the target genome in a variety of ways, some of which can even occur naturally. These methods have led to substantial improvements in many crop species. So what is the problem then?

One common critique is rooted in a longstanding public distrust of science by deeming it "unnatural." Sentiments of this kind are rife in marketing materials. For instance, a recent advertisement for Garden of Life brand probiotic supplements boasts that the pills contain no "bioengineered whatever-they-call-it," while showing a scientist enrobed in a full-body protective suit and respirator holding a sinister-looking test tube containing a sprig of parsley. The corporate website goes so far as to include the bogus remark that "In layman's terms, GMO is a nice way of describing a plant that comes from a seed that has been injected with bacteria or pesticides to help it stay alive when the land it grows in is doused with chemicals."

Another anti-GMO group, The Non-GMO Project, appeals to scientific consensus, but ultimately rehashes the aforementioned anti-intellectual sentiments when it alleges that "there is no scientific consensus on the safety of GMOs."

It might be tempting to think greedy biotech corporations have no regard for safety or sustainability, but this is far from the truth. In reality, the precautionary principle has been judiciously applied to GM crops. New varieties undergo extensive testing prior to introduction, and transgenic materials are heavily regulated. In fact, protocols dictate that every transgenic scrap be labeled and sent off to the autoclave to be sterilized after use.

Genetic modification, in all its forms, is the key to creating new plant varieties that require fewer damaging inputs including fertilizer, pesticides and herbicides, while also providing for the ever-expanding global population. While some valid critiques can be made against some of modern agriculture's practices, the use of GMOs is, by contrast, a scientific triumph. It is especially important to eschew arguments of emotional and anti-intellectual basis. Progress comes through a deference to precaution coupled with an openness to the possibilities of science. Deliberate ignorance concerning genetic modification technology, however well-intentioned, is ultimately misguided.

More here:
The full potential of GMOs is hindered by misinformation - The Reflector online

News Release

Thursday, March 25, 2021

In a study of mice, treatment with the engineered cells shrank tumors and prevented the cancer from spreading to other parts of the body.

Scientists have genetically engineered immune cells, called myeloid cells, to precisely deliver an anticancer signal to organs where cancer may spread. In a study of mice, treatment with the engineered cells shrank tumors and prevented the cancer from spreading to other parts of the body. The study, led by scientists at the National Cancer Institutes (NCI) Center for Cancer Research, part of the National Institutes of Health, was published March 24, 2021, in Cell.

This is a novel approach to immunotherapy that appears to have promise as a potential treatment for metastatic cancer, said the studys leader, Rosandra Kaplan, M.D., of NCIs Center for Cancer Research.

Metastatic cancer cancer that has spread from its original location to other parts of the body is notoriously difficult to treat. Dr. Kaplans team has been exploring another approach: Preventing cancer from spreading in the first place.

Before cancer spreads, it sends out signals that get distant sites ready for the cancers arrival like calling ahead to have the pillows fluffed in your hotel room prior to arrival. These primed and ready sites, discovered by Dr. Kaplan in 2005, are called premetastatic niches.

In the new study, the NCI team explored the behavior of immune cells in the premetastatic niche. Because Dr. Kaplan is a pediatric oncologist, the team mainly studied mice implanted with rhabdomyosarcoma, a type of cancer that develops in the muscles of children and often spreads to their lungs.

To study the premetastatic niche, the researchers looked at the lungs of the mice after tumors formed in the leg muscle but before the cancer was found in the lungs. The immune systems natural ability to attack cancer was present but actively stifled in the lungs, the NCI scientists discovered. There were few cancer-killing immune cells, but many cells that suppress the immune system.

Myeloid cells, in particular, were abundant in the premetastatic niche and continued to gather there as the cancer progressed. Myeloid cells are part of the bodys first response to infection, injury, and cancer. When they detect a threat, they normally make interleukin 12 (IL-12), a signal that alerts and activates other immune cells. But myeloid cells in the lung premetastatic niche instead sent out signals that told cancer-fighting immune cells to stand down, the researchers found.

Together, these features of the lung premetastatic niche allow cancer cells to thrive when they spread there, Dr. Kaplan explained.

The NCI team wondered if they could take advantage of myeloid cells to spur the immune system into action in the premetastatic niche by changing the message they deliver. So, they used genetic engineering to add an extra gene for IL-12 to myeloid cells from lab mice.

We chose myeloid cells to deliver IL-12 based on their unique ability to home to tumors and metastatic sites, Dr. Kaplan said. With IL-12, were turning the volume up on a message thats been quieted.

In mice with rhabdomyosarcoma, these genetically engineered myeloid cells, nicknamed GEMys, produced IL-12 in the primary tumor and in metastatic sites. As hoped, the GEMys recruited and activated cancer-killing immune cells in the premetastatic niche and lowered the signals that suppress the immune system, the researchers found.

We were excited to see that the GEMys changed the conversation in the premetastatic niche. They were now telling other immune cells to get ready to fight the cancer, Dr. Kaplan said.

As a result, mice treated with GEMys had less metastatic cancer in the lungs, smaller tumors in the muscle, and they lived substantially longer than mice treated with nonengineered myeloid cells. The researchers found similar results when they studied mice with pancreatic tumors that spread to the liver.

The NCI team also found that, in combination with chemotherapy, surgery, or T-cell transfer therapy, the effects of the GEMy treatment improved. For example, giving mice a single dose of chemotherapy two days before the GEMy infusion cured mice with rhabdomyosarcoma, meaning the treatment completely eliminated all traces of cancer for more than 100 days.

I have never seen that kind of durable cure in my research before. Typically, cancer growth will slow down after treatment, but then it will come back with a vengeance, Dr. Kaplan said.

The team also found evidence that the chemotherapy and GEMys combination might prevent cancer from coming back. When the researchers reintroduced cancer cells into mice that had been cured by the combination treatment, tumors didnt form. This suggests that the combination treatment leaves a long-lasting immune memory of the cancer, the researchers explained.

As a final step in their study, the researchers created GEMys from human cells grown in the lab. In lab dishes, the genetically engineered human cells produced IL-12 and activated cancer-killing immune cells.

The team plans to test the safety of human GEMys in a clinical trial of adults with cancer and, if it proves to be safe, in children and adolescents with cancer. There are many unanswered questions they hope to explore, including whether the homing pattern of GEMys is similar in humans and mice, and whether IL-12 from the GEMys will cause side effects in patients.

But the researchers are reassured by several factors. We are delivering a small amount of IL-12 thats similar to the bodys natural response to an infection, creating a ripple effect of immune activation against the cancer. In addition, GEMys dont multiply rapidly inside the body, so theyre not flooding the system with IL-12, explained Sabina Kaczanowska, Ph.D., first author of the study. These are important considerations because high levels of IL-12 throughout the body can be toxic.

Although there are challenges of planning a first-in-human trial of a cell therapy, Im grateful to have access to the resources of the NIH Clinical Center and to be able to lean on the experience of my NCI colleagues who have had decades of experience developing cell therapies for cancer, Dr. Kaplan added.

About the Center for Cancer Research (CCR): CCR comprises nearly 250 teams conducting basic, translational, and clinical research in the NCI intramural programan environment supporting innovative science aimed at improving human health. CCRs clinical program is housed at the NIH Clinical Center the worlds largest hospital dedicated to clinical research. For more information about CCR and its programs, visit ccr.cancer.gov.

About the National Cancer Institute (NCI):NCIleads the National Cancer Program and NIHs efforts to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website atcancer.govor call NCIs contact center, the Cancer Information Service, at 1-800-4-CANCER (1-800-422-6237).

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

More:
Engineered immune cells deliver anticancer signal, prevent cancer from spreading - National Institutes of Health

A Facebook user has posted a series of screenshots from the website of the World Mosquito Programme (WMP) alongside news headlines claiming genetically modified insects have been released in Australia. However, the WMP told Reuters this claim is false.

The post, from March 13, consists of seven screenshots in total (here). Five are from the WMP webpage discussing the release of bacteria-laden mosquitoes in northern Australia (worldmosquitoprogram.org). One is from British tabloid The Sun, which has the headline: Bill Gates donates 3 million to create mosquitos that kill each other using SEX (here). The final screenshot shows another headline taken from CBS Miami. It reads: Bill Gates fights for end to mosquito-borne illness (here).

Compiling all the images into one post, the Facebook user then implies they are proof of his argument. Did you know they are releasing genetically modified mosquitos in Australia? Source: mosquitoprogram.org, he writes in the main portion of the post.

However, none of the screenshots offer evidence of this. Firstly, the WMP webpage has nothing to do with genetic engineering. It discusses the process of breeding Aedes Aegypti mosquitoes that are infected with Wolbachia, a type of bacteria that renders the insect less likely to pass specific viruses onto humans (here).

The mosquitoes we release are not genetically modified, a WMP spokesperson told Reuters by email. Wolbachia is a naturally occurring bacteria in 60% of insects. Our process of injecting Wolbachia into Aedes Aegypti mosquitoes does not alter the genetic material of either the Wolbachia bacteria or the mosquito.

Speaking in 2019, Dr Richard Gair, the director of Tropical Public Health Services in Cairns, Australia, credited the WMPs project with mostly eliminating the dengue virus in dengue-prone areas of the region (here). This result came after Cairns recorded one of its worst dengue outbreaks on record during the 2008/09 wet season.

There was a significant public health response at the time, and this was followed by the World Mosquito Program (WMP), formerly Eliminate Dengue, releasing mosquitoes with bacteria called Wolbachia, in 2011, said Gair. Together with our mosquito monitoring and spraying program, the implementation of the WMPs Wolbachia approach has proved highly effective in preventing outbreaks recurring in this region.

Meanwhile, the final two screenshots included in the Facebook post are not related to the WMP. The CBS headline refers to an article about Bill Gates pledging more money to fight tropical disease in general, while The Sun headline refers to Gates donating to a UK-based company researching genetically modified mosquitoes.

Oxitec, a biotechnology company, has released genetically modified mosquitoes with a self-limiting gene in Brazil (here), the Cayman Islands (here) and Panama (here). It plans to also release the insects in Florida and Texas (here). A company spokesperson told Reuters that no such release had taken place in Australia.

The WMP spokesperson told Reuters they believed no genetically modified mosquitoes had been released in Australia. There are, however, studies being carried out in secure Australian labs on mosquitoes and fruit flies (here, here, here). Scientists involved in the mosquito study have also noted that a lot of work will be necessary to encourage community engagement before anything can be released (here).

False. While genetically modified mosquitoes have been released in some countries, they have not been released in Australia. The World Mosquito Programme has released mosquitoes injected with Wolbachia bacteria but this method does not involve genetic modification.

This article was produced by the Reuters Fact Check team. Read more about our fact-checkingwork here.

Read the original here:
Fact Check-The World Mosquito Programme has not released genetically modified insects in Australia - Reuters

By Donna Lu

The silverleaf whitefly (Bemisia tabaci)

Nigel Cattlin/Alamy

One species of whitefly, an aphid-like insect, has incorporated a portion of plant DNA into its genome that protects it from leaf toxins. It seems to be the first known example of so-called horizontal gene transfer between a plant and insect in which the transferred genetic material performs a useful function.

While sequencing the genome of the silverleaf whitefly (Bemisia tabaci), Ted Turlings at the University of Neuchtel in Switzerland and his colleagues discovered a gene known as BtPMaT1, which is found in plants but never previously seen in insects.

Thisgene may have an important function in plants. The plants generate toxins to defend themselves from attack by animals. The team suspects that the BtPMaT1 gene may help plants store these toxins in a harmless form so the plants dont poison themselves.

Similarly, the gene may help the whitefly avoid being poisoned when it eats the plant.

Turlings says the gene transfer event occurred between 35 million and 80 million years ago, when the sweet potato whitefly and other whitefly species that lack the gene split from a common ancestor.

The gene transfer event may have involved viruses that cause disease in plants and are transmitted via the whiteflies. Some DNA from a plant may have been taken up by a virus, transmitted to the whiteflies and then subsequently assimilated into the insects genomes.

[Some] viruses basically incorporate their own genome into the cells of their hosts, says Turlings.

The research suggests that the extent to which horizontal gene transfer occurs in nature is probably underestimated, says Caitlin Byrt at the Australian National University in Canberra.

What this shows is that where theres a really strong pressure for survival on an organism, it can actually borrow genetic information that helps it do that from other organisms, says Byrt.

The researchers demonstrated the function of BtPMaT1 in whiteflies by selectively interfering with the gene using small molecules of RNA.

Disrupting the genes function made the whiteflies susceptible to compounds known as phenolic glycosides that are present in tomato plants.

After feeding on tomato plants that had been genetically modified to produce the RNA molecules, all whiteflies subsequently died.

This demonstrates a mechanism that we could use in engineering crops to basically target plant pests, and target the resistance of crops to plant pests, says Byrt, although she points out that horizontal gene transfer may then allow the pests to evolve resistance to our genetic engineering.

Journal reference: Cell, DOI: 10.1016/j.cell.2021.02.014

Sign up to Wild Wild Life, a free monthly newsletter celebrating the diversity and science of animals, plants and Earths other weird and wonderful inhabitants

More on these topics:

See the original post here:
Plant gene has naturally crossed into insects and helps them feed - New Scientist News

Former White House Trade Adviser Peter Navarro went on Fox News late Tuesday to claim that the nations top infectious disease expert Anthony Fauci engineered the pandemic currently ravaging the globe. Citing a conspiracy theory popular among the fringe and the far right, Navarro claimed it was Fauci himself who unleashed the COVID-19 virus on America by bankrolling the genetic engineering of the virus in a Wuhan lab, a claim for which there is no evidence. Fauci is the father of the actual virus. Faucis the guy, said Navarro, who once cited the Dilbert cartoonist to defend the use of a controversial anti-malaria drug, hydroxychloroquine, to treat COVID but has repeatedly attacked Fauci throughout the pandemic. And basically, we had Fauci not only funding that lab with American taxpayer dollars. He authorized this thing called gain of function research... He allowed the Chinese Communist Party to genetically engineer a virus I call it the Fauci Virus now. If he wants to be the father of something, hes the father of the virus thats killed over a half a million Americans, Navarro said.

Navarro went on to cite the former head of the Centers for Disease Control and Prevention, Robert Redfield, who recently made waves by declaring that if he was to guess, the virus likely originated in a lab in Wuhan. World Health Organization investigators have called that theory extremely unlikely. Conservative websites have routinely tried to tie Fauci to the origins of the virus by claiming that the National Institute of Allergy and Infectious Diseases, which Fauci leads, had provided a Wuhan lab with grant money that went towards creating COVID-19. The NIH did provide grant money to the lab, but there is no evidence it was ever used to fund genetic engineering that created the coronavirus.

Continue reading here:
Peter Navarro Cites Conspiracy Theory to Claim Fauci Is 'Father' of the Coronavirus - The Daily Beast

DUBLIN, March 30, 2021 /PRNewswire/ -- The "Global Cell and Gene Therapy Drug Delivery Devices Market: Focus on Product Type, Commercialized Drug Delivery Devices, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

The global cell and gene therapy drug delivery devices market was valued at $55.75 thousand in 2019, and is expected to reach $375.13 thousand by 2030, registering a CAGR of 16.61% during the forecast.

Cell and gene therapy drug delivery industry is a transformative industry whose full potential is only just beginning to emerge. Cell and gene therapy involves the extraction of cells, protein, or genetic material (DNA) from the donor, and altering them to provide highly personalized therapy. Cell and gene therapies may offer longer-lasting effects than traditional medicines.

One of the significant drugs of the cell and gene therapy industry is CAR-T cell-based medicines, which include both cell therapy and gene therapy. Various market players are actively investing in the research and development of the cell and gene therapy industry. The players are offering improved and new products, which meet the critical needs of patients.

The growth is attributed to major drivers in this market such as the increasing prevalence of cancer and chronic diseases, increased funding in the cell and gene therapy market, rising need to develop novel treatment options for rare diseases, and rising biopharmaceutical R&D expenditure, and rising number of the FDA approvals of cell and gene therapies & clinical trials. The market is expected to grow at a significant growth rate due to various potential opportunities of growth that lie within its domain, which include drug approvals and strong pipeline of cell and gene therapies.

Various new cell and gene-based therapy approaches use biological engineering to improve the immune system's capacity to fight disease while sparing healthy tissues in the body. For instance, there are antibody-based therapies that can make T-cells more effective by increasing their interactions with cancer cells. Other modifications, such as adding complexity to the CAR-T and cancer cell interaction, which can further sharpen T-cells' cancer-targeting ability by reducing damage to normal cells.

The increase in the geriatric population and an increasing number of cancer cases, and genetic disorders across the globe are expected to translate into significantly higher demand for cell and gene therapy drug delivery devices market.

Furthermore, the companies are investing huge amount in research and development of cell and gene therapies and associated drug delivery devices products. The clinical trial landscape of various genetic and chronic diseases has been on the rise in the recent years, this will fuel the cell and gene therapy drug delivery devices market in future.

Within the research report, the market is segmented based on product type, commercialized drugs, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel cell and gene therapy drug delivery devices.

Due to the diverse product portfolio and intense market penetration, Novartis AG, Kite Pharma Inc., and Dendreon Pharmaceuticals LLC. have been the pioneers in this field and been the major competitors in this market.

The other major contributors of the market include companies such as Vericel Corporation, Amgen Inc., Bausch & Lomb Incorporated, Spark Therapeutics, Inc., and Becton, Dickinson and Company.

Based on region, North America holds the largest share of cell and gene therapy drug delivery devices market due to substantial investments made by biotechnology and pharmaceutical companies, improved healthcare infrastructure, rise in per capita income, early availability of approved therapies, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Key Topics Covered:

1 Technology Definition

2 Research Scope

3 Key Questions Answered in the Report

4 Research Methodology

5 Market Overview5.1 Introduction5.2 Cell and Gene Therapies and Drug Delivery Devices Industry5.3 Cell and Gene Therapy Drugs and Their Clinical Importance5.4 Cell and Gene Therapy Drug Delivery Devices Market: Current Scenario5.5 Cell and Gene Therapy Drug Delivery Devices Market: Future Perspective

6 Global Cell and Gene Therapy Drug Delivery Devices Market and Growth Potential, 2020-20306.1 Overview6.2 Pipeline Analysis6.2.1 Drug Delivery Systems in Development: Current Scenario6.2.1.1 Ongoing Clinical Trials of Drug Delivery Systems6.2.1.2 Limitations of Cell and Gene Therapy Drug Delivery Devices6.2.1.3 Recent Advancements in Gene Therapy Drug Delivery6.3 Cell and Gene Therapy Drug Delivery Devices Market and Growth Potential6.4 Cell and Gene Therapy Drug Development and Commercialization Landscape6.5 Impact of COVID-19 on Cell and Gene Therapy Drug Delivery Devices Market6.5.1 Impact of COVID-19 on Global Cell and Gene Therapy Drug Delivery Devices Market Growth Rate6.5.2 Impact of COVID-19 on Supply Chain of Cell and Gene Therapy Drug Delivery Devices Market6.5.3 Clinical Trial Disruptions and Resumptions

7 Emerging Technology Landscape7.1 Potential Technologies in Cell and Gene Therapy Drug Delivery Devices Market7.2 Microchip Technology7.3 Nanotechnology-Based Drug Delivery Devices7.4 Lipid Nanoparticles in Gene Therapy

8 Market Dynamics8.1 Impact Analysis8.2 Market Drivers8.2.1 Increasing Prevalence of Cancer and Chronic Diseases8.2.2 Increased Funding of Cell and Gene Therapies8.2.3 Rising Number of FDA Approvals of Cell and Gene Therapies, and Clinical Trials8.3 Market Restraints8.3.1 Stringent Legal Requirements and Regulations8.3.2 Injuries and Infections Caused by Needles8.4 Market Opportunities8.4.1 Strong Pipeline of Cell and Gene Therapies

9 Industry Insights9.1 Regulatory Scenario of Cell and Gene Therapy Drug Delivery Devices Market9.1.1 Overview9.1.2 Risk Assessment of Medical Devices9.1.3 Regulation of Medical Devices in the U.S.9.1.4 Regulation of Medical Devices in Europe9.1.5 Regulation of Medical Devices in Asia-Pacific9.2 Pricing and Reimbursement of Cell and Gene Therapy Drug Delivery Devices

10 Patent Landscape

11 Global Cell and Gene Therapy Drug Delivery Devices Market (by Product Type)11.1 Overview11.2 Subretinal Injection Cannula11.3 Extension Tube11.4 Intravenous Catheter11.5 Sterile Insulin Syringe11.5.1 Sterile Insulin Syringe (Size 1.0 ML, 31-Gauge Needle)11.5.2 Sterile Insulin Syringe (Size 0.5 ML, 22 Gauge Needle)11.6 Pre-Filled Syringe11.6.1 Pre-Filled Syringe (Size 1.0 ML, 22-26 Gauge Needle)11.6.2 Pre-Filled Syringe (Size 4.0 ML, 22-26 Gauge Needle)11.7 Infusion Bags11.7.1 Infusion Bags (Size 10 ML to 50 ML)11.7.2 Infusion Bags (Size 68 ML)11.7.3 Infusion Bags (Size 60 ML)11.7.4 Infusion Bags (Size Up to 65 ML)

12 Global Cell and Gene Therapy Drug Delivery Devices Market (by Commercialized Drugs)12.1 Commercialized Drugs12.1.1 Luxturna12.1.2 Kymriah12.1.3 Provenge12.1.4 Zolgensma12.1.5 Yescarta12.1.6 Strimvelis

13 Global Cell and Gene Therapy Drug Delivery Devices Market (by Region)13.1 Overview

14 Competitive Landscape14.1 Key Developments and Strategies14.1.1 Overview14.1.2 Regulatory and Legal Developments14.1.3 Synergistic Activities14.1.4 M&A Activities14.1.5 Funding Activities14.2 Market Share Analysis

15 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/2mcxqt

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

View post:
Cell and Gene Therapy Drug Delivery Devices Market, 2030 - Market Opportunities in the Strong Pipeline of Cell and Gene Therapies - PRNewswire